Probius

PUBLIC

Name	Probius
Tagline	Quantum sensing device creating molecular digital twins for biotech AI
Headquarters	Fremont, CA
Founded	2015
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.probius.bio
• LinkedIn: https://www.linkedin.com/in/chaitanya-gupta-2630841/

Executive Summary

PUBLIC Probius is a deep-tech biotech company developing a quantum sensing device to create high-dimensional molecular data for AI-driven biomedical discovery, a bet that hinges on its ability to bridge a critical data gap between physical biology and machine learning models [UCeed, ~2022-2023]. Founded in 2015 by a trio of PhDs with backgrounds in advanced sensors and nanotechnology, the company emerged publicly in September 2022 with the announcement of two senior biopharma executives, framing its smartphone-sized Quantum Electrochemical Spectroscopy (QES) device as a tool to generate 40-dimensional digital twins of biological specimens without reagents [BusinessWire, Sep 2022]. The core differentiation rests on a hardware-first approach to data acquisition, aiming to replace complex, sample-destructive lab workflows with a simple, universal process that produces re-analyzable cloud datasets [Probius.bio, retrieved 2026].

The founding team brings substantial technical credibility, with CEO Emmanuel Quevy's focus on sensor commercialization, co-founder Roger Howe's directorship of the Stanford Nanofabrication Facility, and CTO Chaitanya Gupta's engineering research background at Stanford [The Org, retrieved 2026] [ECE Florida News, Jan 2024]. Public funding disclosures are absent, though corporate records indicate a Series A in 2020 and a Series B in 2023, with investors including UCeed, Heuristic Capital, and Zoic Capital [Crunchbase, retrieved 2026]. The business model combines the sale of proprietary sensing hardware with a cloud software layer for storing and analyzing the resulting digital twins, targeting pharmaceutical R&D and biomedical research labs.

Over the next 12-18 months, the key watchpoints are the transition from technical validation to commercial deployment, the emergence of any named customer or partnership beyond the announced collaboration with SaponiQx and Ginkgo Bioworks [Indian Pharma Post, undated], and clarity on the capital required to scale hardware manufacturing and commercial operations, given the long development cycles inherent to deep-tech biotech hardware. Data Accuracy: YELLOW -- Core technology and team claims are well-sourced from company and investor materials; funding details and commercial traction are not publicly confirmed.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Undisclosed

Company Overview

PUBLIC

Probius is a deep-tech biotech company founded in 2015, based in Fremont, California [Crunchbase, 2026]. The company emerged from stealth in September 2022 with a public announcement of its launch and the hiring of two senior executives [BusinessWire, September 2022]. Its founding team includes Emmanuel P. Quevy, Roger Howe, and Chaitanya Gupta, who are listed as co-founders across corporate entities Probius and ProbiusDx Inc. [The Org, 2026] [F6S, 2026].

The company's primary legal entity appears to be ProbiusDx Inc., which was incorporated in 2016 [The Org, 2026] [F6S, 2026]. Key milestones are sparse in public records. The 2022 launch announcement framed the company's mission as transforming data acquisition for AI in healthcare [BusinessWire, September 2022]. Public sources indicate a strategic collaboration with SaponiQx and Ginkgo Bioworks aimed at vaccine adjuvant development, though the date of this partnership is not specified [Indian Pharma Post]. No subsequent major announcements, product launches, or customer disclosures have been captured in the public record since late 2022.

Data Accuracy: YELLOW -- Company founding and launch confirmed by multiple sources; corporate structure and specific milestone dates are partially corroborated.

Product and Technology

MIXED Probius's core proposition is a hardware device that aims to circumvent the complexity and cost of traditional bioanalytical workflows. The company describes its smartphone-sized instrument as using Quantum Electrochemical Spectroscopy (QES) to measure molecular vibrations directly from a biological sample aliquot, requiring no reagents or extensive preparation [UCeed, ~2022-2023]. This raw physical measurement is then translated into a high-dimensional phenotypic signature, which the company terms a "digital twin" of the specimen [Probius.bio, retrieved 2026]. These 40-dimensional digital representations are stored in a cloud platform, where they are intended to be re-analyzed and mined by AI models for applications in research, disease prediction, and drug development [UCeed, ~2022-2023].

The technology stack is not detailed in public materials, but recent job postings for Sensor Test and Product Test Engineer roles suggest an active hardware development phase focused on characterization, validation, and reliability testing [Lever.co, retrieved 2026]. The primary product claims center on creating large, standardized datasets of proteins, metabolites, and small molecules from diverse organisms, positioning the device as a data generation engine for biology-AI pipelines [Probius LinkedIn, retrieved 2026]. A publicly announced strategic collaboration with SaponiQx and Ginkgo Bioworks aims to apply this quantum molecular spectroscopy to AI-driven vaccine adjuvant discovery, though the commercial terms and technical integration are not disclosed [Indian Pharma Post].

Data Accuracy: YELLOW -- Core product claims are consistent across the company's website and investor portfolio pages, but technical specifications and performance benchmarks are absent. The collaboration is reported in trade press but lacks corroborating detail from the partners.

Market Research

PUBLIC

The market for data acquisition tools in biology is shifting from reagent-based workflows to data-centric pipelines, a transition that creates a new wedge for hardware that can generate high-fidelity, machine-readable molecular signatures. Probius positions its quantum sensing device at this intersection, targeting the growing demand from biomedical researchers and pharmaceutical developers for large, standardized datasets to feed AI models for drug discovery and disease prediction [BusinessWire, Sep 2022].

The total addressable market is not quantified in public sources for Probius's specific quantum sensing hardware. However, analogous markets provide a directional sense of scale. The global AI in drug discovery market was valued at $1.2 billion in 2022 and is projected to reach $4.9 billion by 2028, according to a third-party report cited by the company's investor materials [TSV Capital, ~2022]. The broader bioanalytical instruments market, which includes traditional spectrometers and mass spectrometers, is a multi-billion dollar industry. Probius's SAM would be the segment of researchers and biopharma teams seeking to replace or augment those existing tools with a device promising reagent-free, high-dimensional data output.

Demand drivers are well-documented in adjacent sectors. The push towards AI-driven biology requires vast amounts of consistent, high-quality data, a bottleneck that reagent-intensive and low-throughput traditional methods struggle to address [BusinessWire, Sep 2022]. Tailwinds include increased R&D spending in biopharma, the proliferation of AI/ML startups in life sciences, and a broader industry focus on digital twins for predictive health. The company's stated collaboration with Ginkgo Bioworks on vaccine adjuvant development points to early recognition of this need in synthetic biology [Indian Pharma Post].

Key adjacent and substitute markets include the established fields of mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, and next-generation sequencing (NGS) data generation. These are multi-step, capital-intensive processes. Probius's claimed advantage is a simplified, universal workflow in a smartphone-sized form factor, which, if proven, could appeal to labs seeking faster, cheaper phenotypic screening. Regulatory forces are a consideration for any device used in clinical decision-making or drug development, though the company's initial focus appears to be on research applications.

AI in Drug Discovery 2022 | 1200 | $M
AI in Drug Discovery 2028 | 4900 | $M

The projected near-tripling of the AI drug discovery market by 2028 illustrates the financial tailwind behind tools that can generate better biological data. For Probius, success hinges on capturing a slice of this growth by convincing researchers that its quantum electrochemical spectroscopy (QES) output is a superior data type for training models.

Data Accuracy: YELLOW -- Market sizing is based on an analogous sector report cited in secondary coverage, not a primary source for the device-specific TAM. Demand drivers are corroborated by industry press.

Competitive Landscape

MIXED

Probius operates at a nascent intersection of quantum sensing, biotech, and AI, a space where direct, product-for-product competitors are not yet clearly defined in public sources. The competitive map is therefore best understood as a set of established incumbents in adjacent analytical workflows and a cohort of emerging deep-tech startups pursuing similar long-term visions.

If the structured facts included named competitors, a comparison table would be placed here. No such competitors were identified in the provided sources.

The competitive environment segments into three broad categories. First, incumbent analytical instrument vendors like Agilent, Thermo Fisher Scientific, and Bruker dominate the life sciences research market with established mass spectrometers, NMR systems, and chromatography equipment. These tools are the current gold standard for molecular analysis but are reagent-intensive, require specialized sample preparation and operation, and generate data that is often siloed and not natively structured for AI training [BusinessWire, Sep 2022]. Second, a growing field of AI-first biotech software platforms,such as Recursion Pharmaceuticals, Insitro, or Exscientia,are building sophisticated models for drug discovery. These companies are potential customers or partners for Probius, as they are constrained by the quality and dimensionality of the biological data they can access; they could also become competitors if they develop or acquire their own proprietary data-generation hardware. Third, a handful of early-stage quantum biology or sensor startups are exploring similar ground, though specific names are not publicly linked to Probius. These would be the most direct competitors, competing for the same deep-tech talent, venture capital, and early-adopter research labs.

Probius's claimed edge rests on its proprietary Quantum Electrochemical Spectroscopy (QES) hardware and the resulting data structure. The company's materials position its smartphone-sized device as enabling a "simple universal workflow" without reagents, creating a standardized, high-dimensional (40D) "digital twin" of a biological specimen that is cloud-stored and re-analyzable [Probius.bio, retrieved 2026]. This is a data moat play: if the technology works as described and is adopted, Probius would own a unique and growing dataset of molecular vibrational signatures that could become the training corpus for a new class of AI models in biotech. This edge is potentially durable if protected by patents and accelerated by first-mover deployments, but it is currently perishable,it exists only as a technical claim without published validation or commercial traction.

The company's most significant exposure is its reliance on a novel hardware platform in a market dominated by entrenched incumbents with vast sales and support channels. Probius has not disclosed any distribution partnerships, and its team, while strong in research, shows limited public evidence of scaled commercial execution in life sciences instruments. A specific risk is that large incumbent vendors could develop a "good enough" digital twin capability as a software layer atop their existing installed base, leveraging their customer relationships to outflank a standalone hardware startup. Furthermore, the AI-biotech platforms, as potential customers, may choose to build rather than buy, especially if core sensing physics becomes more accessible.

The most plausible 18-month scenario involves continued stealth development. A "winner" scenario would see Probius announcing a strategic partnership with a major pharma or AI drug discovery company to co-develop assays, providing the first external validation of its technology and data utility. A "loser" scenario would be continued public silence, which, in the absence of funding news, would signal technical hurdles or an inability to secure design-win partners, allowing other early movers in the quantum-bio sensing space to capture mindshare and early adopters.

Data Accuracy: YELLOW -- Competitive analysis is inferred from company positioning and adjacent market segments; no direct competitor names are publicly linked.

Opportunity

PUBLIC If Probius can successfully commercialize its quantum sensing hardware and establish its data format as a standard for AI-ready molecular information, it could unlock a foundational layer for data-driven biology, a market historically constrained by slow, reagent-intensive measurement.

The headline opportunity is to become the primary data-acquisition platform for AI-driven life sciences, a role analogous to Illumina for genomics but for a broader set of molecular phenotypes. The company's core claim is that its Quantum Electrochemical Spectroscopy (QES) device can measure proteins, metabolites, and small molecules from any biological specimen without reagents or complex sample prep, generating a standardized, re-analyzable digital twin [UCeed, ~2022-2023]. This positions it not as another analytical instrument, but as an infrastructure play that could accelerate the shift from wet-lab experimentation to in-silico analysis across drug discovery, diagnostics, and agricultural biology. The strategic collaboration with Ginkgo Bioworks, a leader in organism engineering, provides an early signal that this vision resonates with a major platform company seeking novel data inputs for its AI [Indian Pharma Post]. The outcome is reachable because the bottleneck is real: the industry's move toward AI is currently gated by the scarcity of high-quality, standardized, and abundant molecular data.

Probius's path to scale depends on which application wedge gains initial traction. The following scenarios outline plausible, concrete routes.

Scenario	What happens	Catalyst	Why it's plausible
Pharma Partner Dominance	Probius devices become the standard tool for generating molecular digital twins of compound libraries and patient samples within large pharmaceutical R&D.	A multi-year, enterprise-wide partnership with a top-20 pharma company for adjuvant or biomarker discovery, following the Ginkgo model.	The company explicitly targets drug development and has hired a Chief Scientific Officer, John Baldoni, with a biopharma background to lead these engagements [BusinessWire, Sep 2022].
Research Platform Adoption	The device and cloud data format become ubiquitous in academic and biotech research labs, creating a network effect where published findings rely on Probius data.	Adoption by a major research consortium or national lab as a core technology for a large-scale phenotyping project.	The universal workflow and lack of reagents lower the barrier for academic labs compared to traditional mass spectrometry, aligning with the trend toward data-centric biology [UCeed, ~2022-2023].

Compounding for Probius would manifest as a data format moat. Each digital twin uploaded to its cloud platform increases the value of the entire corpus for AI training. If the QES signature becomes a widely adopted data standard, the cost for customers to switch to a competing hardware platform would rise significantly, as their historical datasets and analytical models would be native to the Probius ecosystem. The company's description of creating "large datasets (digital twins) of samples" stored in the cloud suggests this flywheel is a core part of the design from the outset [Probius LinkedIn, retrieved 2026]. Early partnerships with entities like Ginkgo could seed the platform with valuable, proprietary data that improves the underlying AI models, creating a feedback loop where better models attract more users who generate more data.

The size of the win can be framed by looking at comparable infrastructure providers in adjacent life sciences data markets. Illumina, the dominant provider of DNA sequencing hardware and consumables, achieved a market capitalization exceeding $20 billion at various points, built on being the essential tool for genomic data generation. While Probius operates in a nascent, pre-commercial stage, a successful execution of the Pharma Partner Dominance scenario could position it as a critical, high-margin hardware and data services provider within the $50 billion (estimated) preclinical drug discovery market. If it captures even a single-digit percentage of that spend as a data infrastructure layer, the resulting enterprise value could reach the low billions of dollars (scenario, not a forecast). This outcome is contingent on the technology performing as claimed at scale and achieving commercial adoption, which the available public evidence does not yet confirm.

Data Accuracy: YELLOW -- Core technology and partnership claims are cited, but commercial traction and market size are not publicly quantified.

Sources

PUBLIC

1. [UCeed, ~2022-2023] Probius | https://ucalgary.ca/uceed/about/portfolio/probius

2. [BusinessWire, Sep 2022] Probius Emerges to Transform Data Acquisition for AI in Healthcare adding John Baldoni Chief Scientific Officer and Juan C. Cuevas SVP Marketing and Business Development | https://www.businesswire.com/news/home/20220914005190/en/Probius-Emerges-to-Transform-Data-Acquisition-for-AI-in-Healthcare-adding-John-Baldoni-Chief-Scientific-Officer-and-Juan-C.-Cuevas-SVP-Marketing-and-Business-Development

3. [Probius.bio, retrieved 2026] About Probius | https://www.probius.bio/about-probius/

4. [TSV Capital, ~2022] Probius - Building a Comprehensive Image of Health | https://www.tsvcap.com/post/probius-building-a-comprehensive-image-of-health

5. [Probius LinkedIn, retrieved 2026] Chaitanya Gupta | https://www.linkedin.com/in/chaitanya-gupta-2630841/

6. [The Org, retrieved 2026] Chaitanya Gupta - Co-founder, CTO at ProbiusDx | https://theorg.com/org/probiusdx/org-chart/chaitanya-gupta

7. [ECE Florida News, Jan 2024] Distinguished Seminar: Roger Howe | https://news.ece.ufl.edu/2024/01/29/distinguished-seminar-roger-howe/

8. [Crunchbase, retrieved 2026] Probius - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/probius

9. [Lever.co, retrieved 2026] Probius - Sensor Test & Characterization Engineer | https://jobs.lever.co/ProbiusDx/7e8525e0-490a-4c84-a942-f655323bf380

10. [Indian Pharma Post] Strategic collaboration with SaponiQx and Ginkgo Bioworks to rework vaccine adjuvant development using quantum molecular spectroscopy for AI-driven discovery | https://www.indianpharmapost.com/strategic-collaboration-with-saponix-and-ginkgo-bioworks-to-rework-vaccine-adjuvant-development-using-quantum-molecular-spectroscopy-for-ai-driven-discovery/

11. [F6S, retrieved 2026] ProbiusDx Inc. | https://www.f6s.com/company/probiusdxinc